A Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathwa
A Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathwa
Trametinib 治疗患有难治性肿瘤和 MAPK/ERK 通路激活的儿童神经胶质瘤或丛状神经纤维瘤患者的 2 期研究
批准号：
401189
负责人：
Perreault Sebastien
金额：
$41.8万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-03-01 至 2024-03-01
关键词：
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Low grade gliomas (LGG) are the most frequent brain tumors in children. Whereas, some patients can be cured with surgery alone, a significant number will need complimentary treatments since location such as optic pathway or brainstem precludes resection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway
-
批准号：465505
-
项目类别：Operating Grants
-
资助金额：$33.77万
-
财政年份：2022
-
负责人：Perreault Sebastien
-
依托单位：
海外基金
